Results 201 to 210 of about 22,335 (252)

Serum IGF-1 and the Risk of Cardio-Kidney Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Diabetes Obes Metab
Cho Y, Park HS, Lim TS, Jhee JH, Jhee JH.   +4 more
europepmc   +1 more source

Care Pathways for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-The-Art Review. [PDF]

Liver Int
van Eekhout KMA, Broekman LD, de Jong VD, Michel M, Grobbee R, Maya-Miles D, Romero-Gómez M, Muris J, Mendive JM, Vali Y, Franco OH, Schattenberg JM, Fournier-Poizat C, Castro Cabezas M, Tushuizen ME, Holleboom AG, GRIPonMASH consortium.   +16 more
europepmc   +1 more source

Liver cirrhosis is associated with altered glucocorticoid metabolism related to disease severity

Journal of Internal Medicine, EarlyView.
Abstract Background Liver cirrhosis (LC) is frequently complicated by adrenal dysfunction; however, whether cirrhosis drives the coordinated, pathway‐specific reprogramming of cortisol metabolism remains unclear. Objectives We aimed to characterize axis‐specific alterations in cortisol metabolism in patients with LC, those with adrenal insufficiency ...
Soyeon Park, Min Jeong Park, Hye Won Yang, Jeayeon Park, Su Jong Yu, Seung Shin Park, Man‐Ho Choi, Eun Ju Cho, Jung Hee Kim   +8 more
wiley   +1 more source

Role of Sirtuin 6 in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Curr Issues Mol Biol
Kim Y, Hwang S.
europepmc   +1 more source

Metabolic dysfunction-associated steatotic liver disease in Cushing's syndrome: prevalence, determinants, and changes after remission. [PDF]

Front Endocrinol (Lausanne)
Ucgul E, Menekse B, Cankaya R, Gorgulu MB, Ucan B, Cakal E, Kizilgul M.   +6 more
europepmc   +1 more source

Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease. [PDF]

Front Endocrinol (Lausanne)
Fang K, Miao J, Song G.
europepmc   +1 more source

Histologic metabolic dysfunction–associated steatotic liver disease severity associated with a graded increase in peripheral artery disease risk

Journal of Internal Medicine, EarlyView.
Shuai Yuan, Fahim Ebrahimi, Jiangwei Sun, Hannes Hagström, Carole A. Marxer, Michael G. Clark, Marijana Vujkovic, Scott M. Damrauer, Jonas F. Ludvigsson   +8 more
wiley   +1 more source

Australian Guideline for the Identification and Management of Hypertension in Children and Adolescents

Journal of Paediatrics and Child Health, EarlyView.
N. G. Larkins, T. Medley, A. Black, K. A. Bolton, S. Chaturvedi, M. Clark, G. M. Gabb, J. P. Glenning, C. Grimes, R. C. Huang, A. Hyland, C. Jeffries‐Stokes, L. Kalman, S. Kaul, S. Kim, S. McTaggart, R. Kowalski, S. X. Li, S. McNab, D. Metz, A. S. Mihailidou, J. Monin, M. Nelson, M. Pathak, D. Roebuck, M. P. Schlaich, R. Sleaby, C. Quinlan, J. P. Mynard   +28 more
wiley   +1 more source

Steatotic liver disease

Lancet, The
Steatotic liver disease is the overarching term for conditions characterised by abnormal lipid accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses what was previously termed non-alcoholic fatty liver disease (NAFLD), which is now called metabolic dysfunction-associated steatotic liver disease (MASLD ...
Emmanuel Tsochatzis, Mads Israelsen, Sven Francque   +2 more
exaly   +6 more sources

Phosphatidylethanol in steatotic liver disease [PDF]

Journal of Hepatology
Steatotic liver disease (SLD) encompasses metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and their combination (MetALD). Distinguishing these subclasses relies on accurately assessing current alcohol intake, particularly as subclass-specific drug therapies become available.
Mads Israelsen, Nikolaj Christian Torp, Aleksander Krag   +2 more
exaly   +3 more sources